What were the results of the SCD-HeFT trial of implantable cardioverter-defibrillator (ICD) therapy?

Updated: Oct 11, 2019
  • Author: Daniel M Beyerbach, MD, PhD; Chief Editor: Jeffrey N Rottman, MD  more...
  • Print


In SCD-HeFT, a primary prevention trial reported in 2005 in which subjects with an LVEF of 35% or less and symptoms in NYHA functional class II or III were randomly assigned to 1 of 3 treatment groups—conventional heart failure therapy plus placebo, conventional heart failure therapy plus amiodarone, or conventional heart failure therapy plus ICD implant—ICD therapy, as compared with placebo, was associated with a 23% reduction in the risk of death from any cause and an absolute 7% decrease in mortality over 5 years.

No difference in mortality benefit was shown between subjects with ischemic cardiomyopathy (70% of enrollees) and those with nonischemic cardiomyopathy. ICD therapy benefited only NYHA functional class II subjects. [21]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!